This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Synlogic, Inc. (SYBX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 3.45% and 23.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Synlogic, Inc. (SYBX) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Synlogic, Inc. (SYBX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Synlogic's (SYBX) Begins Phase I Study for PKU Treatment
by Zacks Equity Research
Synlogic (SYBX) initiates phase I study of SYNB1934, a synthetic biotic candidate to treat PKU. The drug is an evolved strain of SYNB1618, another PKU candidate currently undergoing phase II study.
Do Options Traders Know Something About Synlogic (SYBX) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Synlogic (SYBX) stock based on the movements in the options market lately.
Synlogic (SYBX) Catches Eye: Stock Jumps 12.9%
by Zacks Equity Research
Synlogic (SYBX) saw a big move last session, as its shares jumped nearly 13% on the day, amid huge volumes.
Biomarin to File Regulatory Applications for Vosoritide in Q3
by Zacks Equity Research
BioMarin (BMRN) plans to file regulatory applications seeking approval for its achondroplasia candidate, vosoritide, in the third quarter of 2020.
Will Synlogic Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Synlogic.
BioMarin to Begin Early-Stage Study on Gene Therapy for PKU
by Zacks Equity Research
BioMarin (BMRN) is set to initiate dosing in an early-stage clinical study in the first quarter to evaluate its gene therapy candidate, BMN 307, in phenylketonuria, a rare disease affecting the brain.
Can The Uptrend Continue for Synlogic?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Synlogic
Will Synlogic Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Synlogic.
Synlogic Discontinues Development of SYNB1020, Stock Down
by Zacks Equity Research
Synlogic (SYBX) discontinues the development of its early-stage pipeline candidate, SYNB1020, for the treatment of hyperammonemia, following disappointing study results.
Synlogic Enters Oversold Territory
by Zacks Equity Research
Synlogic, Inc. (SYBX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Synlogic (SYBX) Enters Cancer Collaboration with Roche
by Zacks Equity Research
Synlogic (SYBX) announces clinical collaboration with Roche to develop its pre-clinical cancer candidate in combination with Roche's PD-L1 inhibitor, Tecentriq.
Will Synlogic, Inc (SYBX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Synlogic, Inc (SYBX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Synlogic (SYBX) Could Be a Potential Winner
by Zacks Equity Research
Synlogic (SYBX) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.
Synlogic (SYBX) Enters Oversold Territory
by Zacks Equity Research
Synlogic, Inc. (SYBX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Why Synlogic (SYBX) Might Surprise This Earnings Season
by Zacks Equity Research
Synlogic (SYBX) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
Zacks.com highlights: Enterprise Financial Services, LCI Industries, Simpson Manufacturing and Synlogic
by Zacks Equity Research
Zacks.com highlights: Enterprise Financial Services, LCI Industries, Simpson Manufacturing and Synlogic
New Analyst Coverage Puts the Spotlight on These 4 Stocks
by Zacks Equity Research
More analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.